Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.11
Decreased by
-57.14%
|
-0.12
Increased by
+8.33%
|
Oct 14, 22 | -0.06
Increased by
+25.00%
|
-0.12
Increased by
+50.00%
|
Aug 15, 22 | -0.06
Increased by
+75.00%
|
-0.20
Increased by
+70.00%
|
Mar 31, 22 | -0.31 | -0.04
Decreased by
-675.00%
|
Nov 15, 21 | -0.07 | -0.04
Decreased by
-75.00%
|
Aug 12, 21 | -0.08 | -0.04
Decreased by
-100.00%
|
Mar 16, 21 | -0.24 | -0.10
Decreased by
-140.00%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 42.27 K
Decreased by
-57.30%
|
-3.70 M
Decreased by
-105.09%
|
Decreased by
-8.76 K%
Decreased by
-380.34%
|
Jun 30, 22 | 312.86 K
Increased by
+895.07%
|
-1.86 M
Increased by
+5.71%
|
Decreased by
-594.19%
Increased by
+90.52%
|
Mar 31, 22 | 25.66 K
Decreased by
-90.25%
|
-6.00 M
Decreased by
-431.27%
|
Decreased by
-23.36 K%
Decreased by
-5.35 K%
|
Dec 31, 21 | -37.79 K
Decreased by
-160.77%
|
-7.93 M
Decreased by
-63.61%
|
Increased by
+20.99 K%
Increased by
+369.24%
|
Sep 30, 21 | 99.00 K
Decreased by
-14.33%
|
-1.81 M
Increased by
+2.14%
|
Decreased by
-1.82 K%
Decreased by
-14.22%
|
Jun 30, 21 | 31.44 K
Decreased by
-86.12%
|
-1.97 M
Decreased by
-6.61%
|
Decreased by
-6.27 K%
Decreased by
-668.07%
|
Mar 31, 21 | 263.15 K
Increased by
+234.01%
|
-1.13 M
Increased by
+9.54%
|
Decreased by
-428.84%
Increased by
+72.92%
|
Dec 31, 20 | 62.19 K
Decreased by
-37.78%
|
-4.85 M
Decreased by
-349.89%
|
Decreased by
-7.80 K%
Decreased by
-623.09%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.